Results 271 to 280 of about 2,548,043 (302)

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Lancet, The, 2021
Jong-Mu Sun, Toshihiko Doi, Zhigang Li
exaly  

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto   +2 more
exaly  

Line positions, line profiles, and line fitting

2001
Sumner P. Davis, Mark C. Abrams, James W. Brault   +2 more
openaire   +1 more source

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Lancet, The, 2021
Ahmet Sezer, Saadettin Kilickap, Igor N Bondarenko   +2 more
exaly  

Rayleigh-scattering line profiles

Applied Optics, 1983
Andrew T. Young, George W. Kattawar
openaire   +1 more source

Hematology and oncology clinical care during the coronavirus disease 2019 pandemic

Ca-A Cancer Journal for Clinicians, 2020
Manish A Shah, Tsiporah B Shore, Sebastian Mayer   +2 more
exaly  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Marsela Braunstein, Amit M Oza, Stephanie Lheureux   +2 more
exaly  

Cancer Disparities by Race/Ethnicity and Socioeconomic Status

Ca-A Cancer Journal for Clinicians, 2004
Gopal K Singh
exaly  

Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

Ca-A Cancer Journal for Clinicians, 2016
Markus Raderer, Barbara Kiesewetter
exaly  

Line Profiles

2019
openaire   +1 more source